Format

Send to

Choose Destination
Biomed Res Int. 2013;2013:458989. doi: 10.1155/2013/458989. Epub 2013 Sep 9.

Characterization of schizophrenia adverse drug interactions through a network approach and drug classification.

Author information

1
Department of Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, TN 37203, USA ; Center for Quantitative Sciences, Vanderbilt University Medical Center, Nashville, TN 37232, USA.

Abstract

Antipsychotic drugs are medications commonly for schizophrenia (SCZ) treatment, which include two groups: typical and atypical. SCZ patients have multiple comorbidities, and the coadministration of drugs is quite common. This may result in adverse drug-drug interactions, which are events that occur when the effect of a drug is altered by the coadministration of another drug. Therefore, it is important to provide a comprehensive view of these interactions for further coadministration improvement. Here, we extracted SCZ drugs and their adverse drug interactions from the DrugBank and compiled a SCZ-specific adverse drug interaction network. This network included 28 SCZ drugs, 241 non-SCZs, and 991 interactions. By integrating the Anatomical Therapeutic Chemical (ATC) classification with the network analysis, we characterized those interactions. Our results indicated that SCZ drugs tended to have more adverse drug interactions than other drugs. Furthermore, SCZ typical drugs had significant interactions with drugs of the "alimentary tract and metabolism" category while SCZ atypical drugs had significant interactions with drugs of the categories "nervous system" and "antiinfectives for systemic uses." This study is the first to characterize the adverse drug interactions in the course of SCZ treatment and might provide useful information for the future SCZ treatment.

PMID:
24089679
PMCID:
PMC3782118
DOI:
10.1155/2013/458989
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Hindawi Publishing Corporation Icon for PubMed Central
Loading ...
Support Center